Background
==========

Recurrent spontaneous abortion (RSA) is a prevalent complication of pregnancy that occurs in 1--2% of all pregnant women, and it is defined as the occurrence of 2 or more consecutive spontaneous abortions \[[@b1-medscimonit-24-4038]\]. A number of factors are thought to play a role in recurrent abortions, including genetic mutations, chromosomal abnormalities in the fetus, infectious agents, and a variety of environmental factors such as alcohol, tobacco, and caffeine \[[@b2-medscimonit-24-4038]\]. Nevertheless, nearly 50% of RSA cases remain unexplained, and it is likely that this condition is multifactorial in nature \[[@b3-medscimonit-24-4038]\]. Therefore, there is a critical need to identify factors involved in RSA to obtain a clear understanding of its causes. However, RSA is often asymptomatic, and therefore identifying RSA is very difficult. RSA sometimes represents a serious clinical condition that can cause physical and psychological trauma to patients. It would be clinically valuable to identify highly selective biomarkers for RSA to inform patients and minimize trauma. Thus far, a range of factors have been isolated from the plasma of RSA patients and evaluated as predictors of RSA, particularly indoleamine 2,3-dioxygenase and human chorionic gonadotropin (hCG) \[[@b4-medscimonit-24-4038]\]. However, current studies have failed to investigate the role of metabolites in plasma as potential RSA biomarkers.

Metabolomics, which evolved from genomics, transcriptomics, and proteomics, is the systematic analysis of the inventory of metabolites to highlight disease-specific metabolic signatures, which could be used as biomarkers \[[@b5-medscimonit-24-4038]\]. Several techniques can then be used to identify and characterize these metabolites, including nuclear magnetic resonance (NMR), liquid chromatography (LC) coupled with mass spectrometry (MS), and gas chromatography MS (GC-MS) \[[@b6-medscimonit-24-4038]\]. Metabolomics has been successfully applied in the diagnosis of a wide range of diseases, including cancer, cardiovascular diseases, neurodegenerative diseases, and rheumatic diseases \[[@b7-medscimonit-24-4038]\]. Mass-spectrometry-based metabolic profiling is increasingly used to uncover new biomarkers for diagnosis \[[@b8-medscimonit-24-4038]\], prognosis \[[@b9-medscimonit-24-4038]\], pathogenesis clarification and potential therapeutic targets for clinical treatment \[[@b10-medscimonit-24-4038]\].

Chee et al. reported that metabolomics was used to detect the potential of urine metabolites as a non-invasive screening tool for predicting threatened miscarriage \[[@b11-medscimonit-24-4038]\]. And metabolomics was also applied for non-invasive embryo assessment *in vitro* fertilization (IVF) \[[@b12-medscimonit-24-4038]\]. However, this valuable tool has not yet been used for the discovery of new biomarkers for RSA. Consequently, the use of metabolomics might create new options for researchers to identify novel mechanisms and pathways involved in the pathogenesis of RSA.

In the present study, we collected plasma samples from patients with RSA and from women with normal pregnancies which have matched in maternal age, gestational age and body mass index (BMI). We used a variety of GC-MS techniques to discover the different metabolic compositions of the plasma samples. Then, differentially expressed metabolites were verified using a targeted metabolomics method via UPLC-MS. Our overall aim was to identify differential metabolites that could be used as new biomarkers for predicting the RSA.

Material and Methods
====================

Clinical samples
----------------

Fifty RSA patients and 51 control patients were enrolled at the International Peace Maternity and Child Health Hospital of China Welfare Institute (IPMCH) between January 2016 and May 2017. The RSA group included patients who had experienced more than 2 unexplained and consecutive spontaneous abortions at less than 10 weeks of gestation. Those who had genital abnormalities, chronic hypertension; diabetes; liver, kidney, cardiovascular, and thyroid diseases; autoimmune diseases; or infectious diseases were excluded. The control group was composed of women undergoing induced abortions of a normal pregnancy at a gestational age matched to that of the RSA group. None of the study participants had experienced any previous spontaneous abortions and had delivered at least one healthy baby at term. The patients in the control group were not treated with any drugs and had no pregnancy risk factors.

Gestational age was determined by last menstruation period. All patients provided informed written consent, and this investigation was approved by the Ethics Committee of IPMCH. Plasma samples were kept at −80°C until analysis.

Sample preparation and analysis by GC-MS
----------------------------------------

Peripheral venous blood was collected from all study participants using ethylene diamine tetra-acetic acid (EDTA) for anticoagulation. Blood samples were allowed to coagulate for approximately 10--20 minutes and then centrifuged at 2000--3000 rpm for 20 minutes. Then, the supernatant (plasma) was stored at −80°C until analyzed.

Plasma samples were thawed and analyzed by GC-MS using the method described by Peng et al. \[[@b13-medscimonit-24-4038]\]. A 100 μL aliquot of plasma was centrifuged at 15 000 rpm for 10 minutes at 4°C. Then, 50 μL of plasma was spiked with 10 μL of an internal standard (2-chlorophenylalanine, 0.3 mg/mL) and vortexed for 10 seconds. This mixture was then extracted with 150 μL of methanol-acetonitrile (2: 1, v/v) and vortexed for 30 seconds. Samples were cooled for 10 minutes at −20°C and then centrifuged at 15 000 rpm for 10 minutes at 4°C. An aliquot of the 150 μL supernatant was placed in a glass sampling vial and dried under vacuum at room temperature. The residue was first reconstituted in 80 μL of methoxyamine (15 mg/mL in pyridine), vortexed for 30 seconds, and kept at 37°C for 90 minutes. Finally, 80 μL of bis(trimethylsilyl)trifluoroacetamide (BSTFA) (1% trimethylchlorosilane) and 20 μL of n-hexane were added, and the extract was kept at 70°C for 60 minutes.

A 1-μL aliquot of the sample extract was injected in splitless mode onto an Agilent GC-MS system (Agilent, USA). A non-polar DB-5 capillary column (30 m×250 μm ID, J&W Scientific, Folsom, CA, USA) was used for separation, with high purity helium as the carrier gas at a constant flow rate of 1.0 mL/minute. GC temperature programming began at 50°C. This was then followed by ramps of 15°C/minute to 125°C, 5°C/minute to 210°C, 10°C/minute to 270°C, and 20°C/minute to 305°C, with final 5-minute incubation at 305°C. The electron impact (EI) ion source was held at 230°C with a filament bias of −70 V. We used full scan mode (m/z 50--600) and an acquisition rate of 20 spectrum/second in the MS setting.

GC-MS data analysis
-------------------

Data acquired from GC-MS were then characterized by Chroma TOF software (v 4.34, LECO, St Joseph, MI, USA). The resulting data sets were then imported separately into the SIMCA-P+ 14.0 software package (Umetrics, Umeå, Sweden). After mean centering and unit variance scaling, we used principle component analysis (PCA) and orthogonal partial least-squares-discriminant analysis (OPLS-DA) to identify differences between the RSA and control groups. The variable importance in projection (VIP) generated in OPLS-DA processing represents the contribution to the discrimination of each metabolite ion between groups. Variables with a VIP \>1 and *P*\<0.05 were considered to be different variables.

We used a variety of statistical techniques to investigate the significance of each of the metabolites identified, including multivariate analysis, the Student's *t*-test, and the Wilcoxon-Mann-Whitney test. Metabolites responsible for differentiating the RSA group from the control group were those in which multivariate and univariate analysis showed statistical significance (VIP \>1.0 and *P*\<0.05). We then compared the extract masses of all selected metabolites using the Human Metabolome Database \[[@b14-medscimonit-24-4038]\] (*<http://metlin.scripps.edu>*) to identify these compounds. Lastly, we used MetaboAnalyst 3.0 (*<http://www.metaboanalyst.ca/>*) to characterize the potential impact of our selected metabolites \[[@b15-medscimonit-24-4038]\]. The*P* value and impact value threshold, as calculated via the analysis of pathway topology, were set to 0.05 and 0.1.

Validation of deferential metabolites between the RSA and control groups
------------------------------------------------------------------------

We selected 8 metabolites (lactic acid, 5-methoxytryptamine, pyruvic acid, phenylalanine, proline, alanine, threonine, and 3-hydroxybutyric acid) that were quantitatively measured by LC-MS analysis. LC-MS analysis was performed using a Waters UPLC I-class system equipped with a binary solvent pump and a sample manager, coupled with a Waters TQ-XS mass spectrometer equipped with an electrospray interface (Waters, USA). Chromatographic separation was accomplished on an ACQUITY UPLC BEH Amide column (100×2.1 mm ID, packed with 1.7 μm particles, Waters, USA). The mobile phases consisted of 20 mM ammonium formate and 0.1% formic acid (A) and 95% ACN with 20 mM ammonium formate and 0.1% formic acid (B). The mobile phase gradient proceeded from 5% A: 95% B to 60% A: 40% B at a flow rate of 0.4 mL/minute. The autosampler was maintained at 4°C. In order to test the repeatability and stability of the system, the QC sample was randomly inserted into the sample sequence.

Results
=======

Study participants
------------------

The participants' detailed characters are shown in [Table 1](#t1-medscimonit-24-4038){ref-type="table"}.

The average maternal age, gestational age, and the body mass index (BMI) of the patients in the RSA group were 30.9±3.77 years, 9.7±2.34 weeks, and 22.3±3.42 kg/m^2^, respectively. The average age, gestational age, and the BMI of the patients in the control group were 30.35±4.59 years, 8.5±2.25 weeks, and 21.5±2.51 kg/m^2^, respectively. No significant differences were shown in age, gestational age, or BMI between the 2 groups (*P*\>0.05). Therefore, the 2 groups were suitable for the comparison studies. The mean number of spontaneous abortion in the RSA group was 2.78, compared to 0 in the control group (*P*\<0.001).

Metabolomic profiling of plasma samples from the RSA and control groups
-----------------------------------------------------------------------

The PCA score plot, which used 5 components (R2Xcum=0.62, Q2cum=0.0996), showed separate trends when comparing maternal plasma from the RSA group and the control group, as shown in [Figure 1A](#f1-medscimonit-24-4038){ref-type="fig"}. Class separation improved following PLS-DA analysis ([Figure 1B](#f1-medscimonit-24-4038){ref-type="fig"}), which identified three key parameters: R2Xcum, R2Ycum, and Q2cum (0.376, 0.87, and 0.661, respectively). OPLS-DA identified an optimized class separation (R2Xcum=0.448, R2Ycum=0.945, Q2cum=0.592), which indicated that the model exhibited good fit and could predict RSA in an efficient manner ([Figure 1C](#f1-medscimonit-24-4038){ref-type="fig"}). Permutation testing ([Figure 1D](#f1-medscimonit-24-4038){ref-type="fig"}) was performed on the quality of the model and indicated that the model was not over-fitted.

Fifty-four metabolites (VIP \>1and*P*\<0.05) are shown in [Table 2](#t2-medscimonit-24-4038){ref-type="table"}. To more clearly characterize the plasma profile of RSA, we used a novel software called Heatmap Illustrator, version 1.0 (HemI) to draw a heat map based on the intensity levels of 54 markers between the 2 groups, and the heat map is presented in [Figure 2](#f2-medscimonit-24-4038){ref-type="fig"} \[[@b16-medscimonit-24-4038]\].

Metabolic pathway and function analysis
---------------------------------------

Metabolic pathways involving glycine, serine and threonine metabolism (*P*=0.00529, impact=0.26) and beta-alanine (*P*=0.0284, impact=0.27) along with the TCA cycle (*P*=0.0113, impact=0.19), phenylalanine metabolism (*P*=0.0217, impact=0.17), and glycolysis (*P*=0.037, impact=0.1) were highlighted as targets for investigating the pathological mechanisms underlying RSA (showed in [Figure 3](#f3-medscimonit-24-4038){ref-type="fig"}).

Validation of metabolites in the RSA and control groups
-------------------------------------------------------

Eight amino acids and biogenic amines (lactic acid, 5-methoxytryptamine, pyruvic acid, phenylalanine, proline, alanine, threonine, and 3-hydroxybutyric acid) were quantitatively measured. The concentration of lactic acid in RSA was higher than that in the control group (*P*\<0.05). Additionally, 5-methoxytryptamine concentration was significantly lower in the RSA group (*P*\<0.05). There was no significant difference in pyruvic acid, phenylalanine, proline, alanine, threonine, and 3-hydroxybutyric acid between groups.

Discussion
==========

Our study indicated that metabolic profiling in unexplained RSA were significantly different from the control group and 54 potential metabolites were identified by using GC-TOFMS. The OPLS-DA models derived from the metabonomic analysis showed clear separation between groups. Furthermore, targeted UPLC-MS/MS was performed to validate metabolites differentially expressed between the RSA and control groups in a more reliable and robust manner \[[@b17-medscimonit-24-4038]\].

Feng et al. \[[@b18-medscimonit-24-4038]\] discovered the metabolic profile in plasma in the threatened abortion of women with polycystic ovary syndrome (PCOS) was significantly altered. The metabolomic approach was also applied in our study, showing distinct profiles of metabolites between RSA and control group. Other research reported \[[@b19-medscimonit-24-4038]\] that in missed abortion, metabolism was disturbed significantly and glyceric acid, indole and sphingosine were found satisfactory metabolites in diagnosis for missed abortion. While the metabolism in RSA is still not reported. In our present study, metabolic pathway impact analysis identified glycine, serine, threonine metabolism, beta-alanine metabolism, the TCA cycle, and phenylalanine metabolism as key biological pathways in the development of RSA. Furthermore, we found significant differences in 5-methoxytryptamine and lactic acid concentrations in RSA patients using LC-MS. Lactic acid arises as a byproduct of anaerobic metabolism. In cases involving sepsis and septic shock, there is a clear increase in the production and clearance of lactic acid leading to lactic acidosis. This condition can be caused by arterial hypotension, microcirculatory dysfunction, and the reduced extraction of oxygen from the peripheral tissues. Albright et al. found that elevated levels of lactic acid in pregnant women were associated with adverse maternal outcomes \[[@b20-medscimonit-24-4038]\]. The process of implantation shares similarities with the pro-inflammatory response. Similar to the findings of Albright et al., we also found elevated lactic acid levels in our RSA group. Metabolic pathways showed that the impact of glycolysis was 0.1 (*P*=0.037), which implies that lactic acid may play a role in the pathological mechanisms underlying RSA. 5-methoxytryptamine is biosynthesized via the deacetylation of melatonin, which occurs naturally in the body at low levels \[[@b21-medscimonit-24-4038]\]. It is a strong *in vitro* or *in vivo* antioxidant \[[@b22-medscimonit-24-4038]\]. Lower 5-methoxytryptamine concentration may play a role in the pathogenesis of RSA. Further exploration is necessary to verify that.

There were some potential limitations of this study when interpreting our conclusions. First, the number of patients in this study was relatively small. Second, it is imperative that further validation experiments are performed in future prospective investigations that involve a larger number of people with RSA. Therefore, our findings can only provide indirect evidence for the pathogenesis of RSA.

To summarize, we investigated differences in metabolites in the plasma of RSA patients. This study suggests that plasma metabolic profiling has great potential in differentiating RSA patients from control patients, and the metabolism of lactic acid and 5-methoxytryptamine is significantly different between RSA and control groups, implying that the differential metabolites might be novel biomarkers of RSA.

Conclusions
===========

Metabolic screening was conducted via GC-MS to identify clear metabolic differences between RSA patients and a control group. LC-MS quantitative analysis showed that lactic acid and 5-methoxytryptamine concentrations in RSA patients were significantly different from a control group.
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###### 

Demographic and clinical details of study participants with RSA compared to the control group.

                                    RSA         Control      *P*
  --------------------------------- ----------- ------------ ---------
  Sample numbers                    50          51           
  Maternal age (y)                  30.9±3.77   30.35±4.59   NS
  Gestational age (wk)              9.7±2.34    8.5±2.25     NS
  BMI (kg/m^2^)                     22.3±3.42   21.5±2.51    NS
  Number of spontaneous abortions   2.75±0.45   0            \<0.001

RSA -- recurrent spontaneous abortion; BMI -- body mass index; Data are expressed as mean ±SD. Gestational age of subjects represents the time at which plasma samples were collected. NS -- not significant.

###### 

Potential metabolites associated with RSA and their metabolic pathways.

  Mass   R.T. (min)   Metabolites                     Related pathway                             VIP value   FC (R/C)   *p* Value
  ------ ------------ ------------------------------- ------------------------------------------- ----------- ---------- -----------
  234    7.29         3-hydroxybutyric acid           Fatty acid Biosynthesis                     1.23        0.41       0.02
  180    19.40        Oleic acid                      Not available                               1.29        0.43       0.02
  174    5.79         Pyruvic acid                    TCA cycle                                   1.42        0.58       0.005
  201    12.73        Alpha-ketoglutaric acid         TCA cycle                                   1.07        0.63       0.03
  174    18.38        5-Methoxytryptamine             Not available                               1.38        0.67       0.01
  218    10.00        Serine                          Glycine, serine, and threonine metabolism   1.39        1.33       0.009
  152    5.70         2-hydroxypyridine               Not available                               1.39        1.34       0.03
  83     6.48         20alpha-Hydroxycholesterol      Steroidogenesis                             1.37        1.34       0.04
  117    14.89        2-Deoxyerythritol               Not available                               1.38        1.34       0.03
  185    22.99        Methyl Palmitoleate             Not available                               1.40        1.34       0.04
  218    10.34        Threonine                       Glycine, serine, and threonine metabolism   1.17        1.35       0.02
  218    13.38        Phenylalanine                   Phenylalanine and tyrosine metabolism       1.10        1.35       0.02
  149    21.68        Dioctyl phthalate               Not available                               1.41        1.35       0.02
  121    5.22         p-benzoquinone                  Pyrimidine metabolism                       1.40        1.36       0.04
  285    9.55         Phenylacetic acid               Phenylacetate metabolism                    1.37        1.37       0.03
  215    10.07        Pelargonic acid                 Not available                               1.36        1.38       0.04
  192    12.70        L-kynurenine                    Tryptophan metabolism                       1.06        1.41       0.04
  218    8.06         Valine                          Valine, leucine, and isoleucine             1.23        1.43       0.02
  130    4.97         N-Ethylglycine                  Not available                               1.27        1.45       0.04
  174    18.49        Noradrenaline                   Not available                               1.03        1.46       0.02
  211    24.29        D-(glycerol 1-phosphate)        Glycerolipid metabolism                     1.37        1.48       0.04
  369    25.35        Cholesterol                     Steroid biosynthesis                        1.37        1.48       0.04
  130    7.46         N-Methyl-DL-alanine             Not available                               1.20        1.49       0.02
  218    10.81        Aminomalonic acid               Not available                               1.34        1.50       0.004
  217    11.87        Threitol                        Not available                               1.38        1.51       0.007
  245    9.91         Fumaric acid                    TCA cycle                                   1.25        1.52       0.04
  262    13.49        6-deoxy-D-glucose               Not available                               1.37        1.52       0.006
  180    18.30        Guanidinosuccinic acid          Not available                               1.25        1.54       0.02
  217    17.09        Galactinol                      Galactose metabolism                        1.43        1.54       0.009
  158    9.13         Isoleucine                      Valine, leucine, and isoleucine             1.22        1.55       0.008
  164    6.31         4-hydroxyphenylpyruvate         Phenylalanine and tyrosine metabolism       1.27        1.55       0.04
  216    13.05        3-hydroxy-L-proline             Not available                               1.46        1.56       0.002
  117    5.19         Lactic acid                     Pyruvate metabolism                         1.09        1.57       0.02
  217    13.91        Threo-beta-hydroxyaspartate     Not available                               1.37        1.58       0.006
  202    21.49        Indolelactate                   Not available                               1.26        1.65       0.015
  218    16.13        D-Arabitol                      Not available                               1.26        1.66       0.017
  158    12.49        N-acetyl-L-aspartic acid        Aspartate metabolism                        1.43        1.67       0.004
  369    7.36         Gallic acid                     Not available                               1.16        1.67       0.03
  248    5.30         Beta-Alanine                    Beta-alanine metabolism                     1.13        1.68       0.04
  212    7.74         4-Androsten-19-ol-3,17-dione    Not available                               1.27        1.70       0.03
  179    19.75        dl-p-Hydroxyphenyllactic acid   Not available                               1.22        1.72       0.01
  212    7.67         Phosphomycin                    Not available                               1.39        1.73       0.02
  156    9.66         Pipecolinic acid                Not available                               1.17        1.74       0.02
  248    14.72        Aconitic Acid                   TCA cycle                                   1.72        1.75       \<0.001
  217    15.68        Xylitol                         Not available                               1.42        1.86       0.006
  116    6.51         Alanine                         Alanine metabolism                          1.47        1.87       0.005
  262    11.22        Erythrose                       Not available                               1.63        1.89       \<0.001
  221    10.51        Malonic acid                    Aspartate metabolism                        1.15        1.92       0.02
  262    12.41        N-Methyl-L-glutamic acid        Not available                               1.31        1.93       0.007
  188    9.43         2,3-Dihydroxypyridine           Not available                               1.55        2.00       \<0.001
  142    9.22         Proline                         Proline metabolism                          1.57        2.03       0.004
  202    19.28        Trehalose-6-phosphate           Not available                               1.76        2.56       \<0.001
  102    6.77         3-Aminoisobutyric acid          Pyrimidine metabolism                       1.63        2.63       \<0.001
  295    15.23        Terephthalic acid               Not available                               1.57        2.64       0.002

VIP -- variable importance in projection; FC (R/C) -- the ratio of relative amounts of RSA group to control group; TCA cycle -- tricarboxylic acid cycle.
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